It was suggested that molecular single gene testing for Fragile X, Rett Syndrome, and PTEN will complement CMA and/or traditional cytogenetics in a clinical setting for neurodevelopmental/ASD disorder diagnosis (Schaefer et al., 2013). This evidence concerns the gene PTEN and atypical Rett syndrome.